Launching Megabrands in Pharmaceuticals

14
Launching Pharmaceutical Megabrands

description

A study of the best practices at the top 13 pharmaceutical global companies

Transcript of Launching Megabrands in Pharmaceuticals

Page 1: Launching Megabrands in Pharmaceuticals

Launching Pharmaceutical Megabrands

Page 2: Launching Megabrands in Pharmaceuticals

Start Early.

• Its not how much money companies spend on marketing, but how well they spend it.

• Allocate marketing resources as early as the Pre-Clinical Phase

• Identify unmet medical needs, market opportunities and competitive issues

Page 3: Launching Megabrands in Pharmaceuticals

Early inputs from Marketing teamMarketing inputs to guide the Drug development Process

Market needs analysis

Improved product positioning and market acceptance.

Page 4: Launching Megabrands in Pharmaceuticals

One core Team

Employ cross-functional teams, based on the specific needs of each development phase

•Seamless phase-to-phase transition through early planning and retention of core team members

Partnership between R&D and marketing

As early as the Pre-Clinical Phase

Page 5: Launching Megabrands in Pharmaceuticals

Good communication

• deploy robust technologies that enable rapid information sharing.

• Increase ease and frequency of face-to- face communication through co-location and regular meetings.

Page 6: Launching Megabrands in Pharmaceuticals

Broad-based market research complex and evolving customer needs and competitive dynamics

• employ market segmentation research tools

• understand attitudes behaviors of patients and consumers as well as physician prescribers and pharmacists.

• understand the needs of payors, professionals and patient advocacy groups

Page 7: Launching Megabrands in Pharmaceuticals

Good use of Thought leaders

Prioritize thought leaders by hierarchy of impact (global vs. continent or country unit).

• Involve both research-focused thought leaders and patient-focused thought leaders

• Thought leaders to provide consistent support throughout the entire product development and launch cycle.

Page 8: Launching Megabrands in Pharmaceuticals

What questions should thought leaders consider• What studies are needed for promotional use?

• What new indications should be pursued? What clinical research might need to be conducted for additional indications in Phase IV?

• What competitive products are on the horizon, and what advantages are they expected to claim?

• What is the predicted response of other practicing physicians to the current labeling, dosage and indications?

Page 9: Launching Megabrands in Pharmaceuticals

Pre-launch activities

CME programs

Scientific meetings and symposia

Public relations

Medical publications

Thought leader and advocacy group development

Disease awareness programs

Page 10: Launching Megabrands in Pharmaceuticals

Launch and post-launchBuild upon pre-launch market development activities

• Field force detailing and sampling

• DTC marketing • CME programs • Professional journal advertising

Page 11: Launching Megabrands in Pharmaceuticals

How do top companies spend their money ?

Page 12: Launching Megabrands in Pharmaceuticals

New opportunities in the Digital world

Page 13: Launching Megabrands in Pharmaceuticals

Social MediaOvercrowded and unregulated

• Provides a new but unknown medium• Social networking docs write more scripts.-New

Study• >70% onliners have searched for health information

Page 14: Launching Megabrands in Pharmaceuticals

Dr.Neelesh BhandariM.B.B.S (AFMC),M.D (Path)P.G.P in Human Rights

Advisor ( Medical Communications)Mark IV Animation Studios Pvt. Ltd.

 

- Medical Animation Library - 2D/3D Medical & Scientific Illustrations - 2D/3D Medical & Scientific Animations - Flash based Interactive Applications - Websites & Health Portals for Pharmaceutical & Healthcare Industry